Preferred Label : Vociprotafib;
NCIt synonyms : PTPN11 Inhibitor RMC-4630; SHP2 Inhibitor RMC-4630; (6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)-
5-methylpyrazin-2-yl)methanol; 2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-;
NCIt definition : An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor
type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic
activity. Upon oral administration, vociprotafib targets, binds to and inhibits the
activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and
prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed
in a variety of cancer cell types, regulates cell survival, differentiation and proliferation
through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway
is often hyperactivated in cancer cells due to specific mutations and rearrangements
and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed
cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint
modulation.;
UNII : C4YBF9170L;
CAS number : 2172652-48-9;
Molecule name : RMC-4630; RMC 4630; SAR-442720; SAR 442720;
NCI Metathesaurus CUI : CL562678;
Origin ID : C155850;
UMLS CUI : C5783371;
Semantic type(s)
- concept_is_in_subset
- has_target
